Biogen Earnings Call Highlights Turnaround Momentum

Biogen Inc. ((BIIB)) has held its Q1 earnings call. Read on for the main highlights of the call.

Biogen’s latest earnings call struck a cautiously optimistic tone, blending solid EPS growth and accelerating newer products with frank discussion of near‑term headwinds from investment spending, IPR&D charges and regulatory risk. Management stressed confident execution, strong cash generation and strategic optionality, while acknowledging only modest top-line growth and some commercial lumpiness.

Strong Q1 Performance and Balance Sheet

Biogen reported Q1 revenue of $2.5 billion, up 2% year over year, with GAAP diluted EPS climbing 31% to $2.15 and non-GAAP EPS up 18% to $3.57. The company generated $594 million of free cash flow, ending the quarter with $4.7 billion in cash and marketable securities and net debt of $1.5 billion, giving it ample financial flexibility.

Growth Products Overtake Legacy MS Portfolio

Growth products delivered $851 million in revenue, rising 12% year over year and, for the first time, surpassing the contribution from the remaining multiple sclerosis portfolio. This shift underscores Biogen’s progress in pivoting away from declining legacy franchises toward a more diversified base of neurology, rare disease and immunology assets.

LEQEMBI Adoption, Persistence and Next-Step Innovations

LEQEMBI generated $168 million in Q1 revenue, up 74% year over year, and continues to lead by total patient share in the U.S., Japan and China. Real-world treatment persistence is running near 80% at 18 months and roughly 70% at two years, and an upcoming regulatory decision for the IQLIK initiation regimen could further improve convenience and competitiveness.

SKYCLARYS Global Launch Gains Traction

SKYCLARYS posted $151 million in Q1 revenue, a 22% year-over-year increase, with especially strong momentum outside the U.S. The drug is now available in 35 countries, and Biogen highlighted ongoing ex-U.S. demand growth and sequential patient uptake as key pillars of its rare-disease expansion.

SPINRAZA High-Dose Rollout Shows Early Promise

High-dose SPINRAZA has been approved in the U.S., Japan and Europe, and Biogen is already seeing early patient starts. Management cited positive anecdotal reports of switches and back-switches, including an early reference point of about 20% conversion in Germany, suggesting potential to stabilize or reignite this important spinal muscular atrophy franchise.

Pipeline Progress and Long-Term Readout Cadence

Biogen detailed meaningful pipeline progress, including durable one-year benefit data for Salanersen in children previously treated with gene therapy and first-patient dosing in the pivotal STELLA-1 study. Positive Phase II data for litifilimab in SLE and CLE and a multiyear flow of registrational readouts from 2026 onward position the company for sustained data-driven catalysts.

Strategic Apellis Deal to Bolster Growth Profile

The proposed Apellis acquisition, adding SYFOVRE and Empaveli, is designed to deepen Biogen’s immunology and rare disease presence and materially lift its earnings outlook. The deal will be funded with about $3.6 billion of cash and $2 billion in borrowings, and management expects it to be accretive to non-GAAP EPS in 2027 and the new debt to be repaid by the end of that year.

Felzartamab and Nephrology Franchise Expansion

Biogen acquired China rights to felzartamab through its TJ Bio transaction, fortifying its nephrology pipeline. Management expressed growing conviction in the asset’s potential, pointing to anticipated Phase III readouts in antibody-mediated rejection and a meaningful opportunity in IgA nephropathy and broader kidney disease markets.

Balancing Cost Discipline with Targeted Investment

Non-GAAP core operating expenses came in around $1.1 billion for the quarter, reflecting higher R&D and SG&A to support late-stage trials and new launches. Executives emphasized that despite these increases, they remain disciplined on overall cost structure while selectively funding programs and commercial efforts that can drive long-term value.

Strong Cash Flow Underpins Capital Allocation Flexibility

With $594 million of free cash flow in Q1, Biogen highlighted its capacity to fund internal R&D, commercial build-outs and strategic M&A like Apellis. The company reiterated plans to deleverage after the acquisition using ongoing cash generation, preserving balance-sheet strength while pursuing growth.

Top-Line Growth Still Modest Despite Mix Shift

Total revenue grew just 2% year over year, underscoring that Biogen remains in an early stage of its turnaround from prior declines. While the stronger performance of newer assets is encouraging, the overall revenue trajectory still hinges on sustaining launch momentum and offsetting erosion in legacy products.

Inventory and Timing Create Revenue Lumpiness

Management cautioned that quarterly results can be noisy due to shipment timing and one-off items, including a VAT-related event and SPINRAZA shipment patterns. SKYCLARYS U.S. revenue also felt the impact of inventory cycles and fewer buying weeks in Q1, making underlying demand trends look lumpier than they are.

Acquired IPR&D Charges Depress Near-Term EPS

Biogen booked about $34 million of acquired IPR&D in Q1, or roughly $0.20 per share, and expects approximately $145 million, around $0.80 per share, in Q2 tied to deals like TJ Bio and a STELLA-1 milestone. These accounting charges weigh on near-term EPS but reflect active investment in external innovation and pipeline expansion.

Higher R&D and SG&A Weigh on Margins

Non-GAAP R&D spending reached $480 million and SG&A $600 million, both up versus last year as Biogen ramps Phase III programs, prelaunch activities and marketing, including direct-to-consumer initiatives. While these investments are aimed at driving future growth, they pressure operating margins in the short run and will be watched closely by investors.

Key Regulatory and Clinical Risks Ahead

The company faces several binary events, including a regulatory decision on LEQEMBI’s subcutaneous induction regimen, which could shape its competitive profile. Biogen also acknowledged scientific risk around pioneering assets such as BIIB080, noting uncertainty over whether biomarker reductions will translate into cognitive benefit and a downsized study design that reflects this risk.

Short-Term Leverage and Financing Effects from Apellis Deal

Funding the Apellis acquisition with $2 billion of bank borrowings will temporarily increase Biogen’s leverage and reduce interest income. Management guided to a $120 million to $130 million hit to 2026 non-GAAP other income and expense from financing costs and forgone interest but expects this to ease as the new debt is repaid.

U.S. SKYCLARYS Uptake Faces Commercial Friction

U.S. SKYCLARYS adoption is running slower and more uneven than initially hoped, in part because patients tend to be older and slower progressors, making identification and conversion more challenging. Biogen is leaning on more targeted field work and education to build demand, suggesting a gradual rather than explosive ramp in this market.

Competitive Pressures in Ophthalmology for SYFOVRE

Management acknowledged an increasingly crowded ophthalmology landscape for SYFOVRE, with rival C5-targeting candidates and other approaches emerging. Biogen and Apellis are betting that longer-term safety and efficacy data, including multi-year outcomes, can differentiate the product, though competitive uncertainty remains a key risk.

Guidance and Outlook Emphasize 2026 and Beyond

Biogen reaffirmed its underlying 2026 outlook, guiding to about $600 million in contract manufacturing revenue that will be weighted toward the first half of that year and expecting Q2 core operating expenses broadly in line with Q1. The company flagged the sizable Q2 IPR&D charges and the Apellis financing impact for 2026, while reiterating that the acquisition should begin boosting non-GAAP EPS in 2027 as it leans on robust cash generation to deleverage.

Biogen’s call painted a picture of a company transitioning from defense to offense, with newer drugs and a fuller pipeline starting to outweigh legacy drag. Investors will need to look past near-term earnings noise and spending pressure, but if execution on launches, data readouts and Apellis integration stays on track, the long-term growth story is gaining credibility.